McKesson (MCK) Q2 2027 Earnings
How Did MCK Stock React to Q2 2027 Earnings?
Did MCK Beat Earnings? Q2 2027 Results
Yes. McKesson reported Q2 2027 earnings of $11.68 a share on Nov 4, 2026, beating the $10.75 consensus estimate by 8.6%. Revenue was $111.0B against a $110.0B estimate.
McKesson delivered a strong fiscal second-quarter beat, extending its consecutive EPS consensus-beating streak to five quarters as adjusted earnings of $11.68 per diluted share cleared the $10.75 Wall Street estimate by 8.62%, while revenue of $110.96 billion edged 0.91% above expectations and rose 7.6% from a year ago. The primary engine behind the outperformance was North American Pharmaceutical, where adjusted operating profit surged 22% to $1.04 billion on robust specialty distribution volumes to health systems and strategic accounts, complemented by a 24% revenue jump in Oncology and Multispecialty on broader provider solutions demand. Those gains more than absorbed a 10% profit decline in Medical-Surgical Solutions, a segment McKesson is actively preparing to spin off as a standalone company. Management responded to the quarter's momentum by raising full-year adjusted EPS guidance to $45.60 to $46.40, implying 17% to 19% growth, underscoring confidence in the core distribution and specialty businesses heading into the back half of fiscal 2027.
- Increased prescription transaction volumes in North American Pharmaceutical, including specialty products to health systems and strategic accounts
- Growth in provider solutions and specialty distribution in Oncology & Multispecialty (revenue +24%)
- Higher demand for access solutions in Prescription Technology Solutions (adjusted operating profit +18%)
- Growth across extended and ambulatory care channels in Medical-Surgical Solutions revenue
- Lower diluted share count (116.7M vs 124.4M) supporting adjusted EPS growth of 18%
- Lower contributions from branded pharmaceuticals partially offset revenue growth
- Medical-Surgical adjusted operating profit fell 10% due to unfavorable ambulatory care product mix
“McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise.”
McKesson CEO, on the earnings call
What Is McKesson's Outlook?
McKesson raised its fiscal 2027 Adjusted Earnings per Diluted Share guidance to $45.60–$46.40 from the previous range of $44.20–$45.00, implying 17% to 19% growth over the prior year. The company does not forecast GAAP EPS because it cannot reasonably predict LIFO adjustments, litigation contingencies, transaction-related items and restructuring charges. Additional modeling considerations will be provided in the earnings call presentation.
MCK YoY Financials
| Metric | Q2 2027 | Q2 2026 | Year over year |
|---|---|---|---|
| Revenue | $111.0B | $103.1B | +7.6% |
| Gross Profit | $4.0B | $3.5B | +11.7% |
| Operating Income | $1.6B | $1.5B | +9.3% |
| Net Income | $1.2B | $1.1B | +9.7% |
MCK Revenue by Segment
When Does McKesson Report Next?
Figures from SEC filings and company reports. Not investment advice.